Patents by Inventor Hidenori Akatsuka
Hidenori Akatsuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9751846Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: July 8, 2016Date of Patent: September 5, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Publication number: 20160362385Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: ApplicationFiled: July 8, 2016Publication date: December 15, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki OKABE, Takeshi HAMADA, Kaori TOMIKAWA, Yukie OKAMOTO, Toru IIJIMA, Hidenori AKATSUKA, Kenichi TOYAMA, Atsushi MORODA, Yoshihiro SUGIURA
-
Patent number: 9409874Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: August 8, 2013Date of Patent: August 9, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Publication number: 20150218113Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: ApplicationFiled: August 8, 2013Publication date: August 6, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Patent number: 8975252Abstract: The present invention provides a morpholine derivative of the formula [I]; wherein R1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R3, R4, R5 and R6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.Type: GrantFiled: June 16, 2008Date of Patent: March 10, 2015Assignees: Shanghai Pharmaceuticals Holding Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Hidenori Akatsuka, Hiroshi Sugama, Nobumasa Awai, Takayuki Kawaguchi, Yoichi Takahashi, Toru Iijima, Jingkang Shen, Guangxin Xia, Jianshu Xie
-
Patent number: 8516992Abstract: In some embodiments, a throttle control device includes an axel 43 for opening and closing a throttle valve 41, an axel sensor 52 for detecting an operation amount of the axel 43, a throttle control portion 71 for controlling the throttle valve 41, a memory portion 72 for storing a plurality of control modes 81, 82, and 83 in which a targeted throttle opening degree for the operation amount is determined, a change-over switch 122 for instructing the changing of the control mode, a judgment portion 73a for judging whether or not the operation amount of the axel 43 is equal to or less than the predetermined operation amount, and a changing portion 73b for changing the control mode when the switch 122 is operated and the operation amount of the axel 43 is equal to or less than the predetermined operation amount.Type: GrantFiled: September 2, 2009Date of Patent: August 27, 2013Assignee: Yamaha Hatsudoki Kabushiki KaishaInventor: Hidenori Akatsuka
-
Patent number: 8410166Abstract: Fused bicyclic compound having an affinity to mineral corticoid receptor (MR), of formula [I]: wherein ring A is benzene having a substituent R1, fused to an adjacent 6-membered heterocyclic ring and further optionally having a substituent(s) other than R1, R1 is alkylsulfonylamino, etc., R2 and R3 are (a) the same of different and are hydrogen, alkyl, or optionally substituted aryl, or (b) combined with each other to form an oxo group or (c) combined with each other at its terminal together with the adjacent carbon atom to form cycloalkyl, X is ?N—, ?C(R4)— or —CH(R4)—, R4 is (a) hydrogen, (b) cyano, (c) halogen, (d) alkyl, (e) alkenyl, (f) cycloalkyl, (g) alkanoyl, (h) carbamoyl, or (i) cycloalkenyl, Ar is an optionally substituted aromatic cyclic group and a dotted line means presence or absence of a double bond, or a pharmaceutically acceptable salt thereof, useful e.g. as an antihypertensive agent.Type: GrantFiled: July 30, 2012Date of Patent: April 2, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yoichi Takahashi, Nobumasa Awai, Hidenori Akatsuka, Takayuki Kawaguchi, Toru Iljima
-
Publication number: 20130029979Abstract: Fused bicyclic compound having an affinity to mineral corticoid receptor (MR), of formula [I]: wherein ring A is benzene having a substituent R1, fused to an adjacent 6-membered heterocyclic ring and further optionally having a substituent(s) other than R1, R1 is alkylsulfonylamino, etc., R2 and R3 are (a) the same of different and are hydrogen, alkyl, or optionally substituted aryl, or (b) combined with each other to form an oxo group or (c) combined with each other at its terminal together with the adjacent carbon atom to form cycloalkyl, X is ?N—, ?C(R4)— or —CH(R4)—, R4 is (a) hydrogen, (b) cyano, (c) halogen, (d) alkyl, (e) alkenyl, (f) cycloalkyl, (g) alkanoyl, (h) carbamoyl, or (i) cycloalkenyl, Ar is an optionally substituted aromatic cyclic group and a dotted line means presence or absence of a double bond, or a pharmaceutically acceptable salt thereof, useful e.g. as an antihypertensive agent.Type: ApplicationFiled: July 30, 2012Publication date: January 31, 2013Inventors: Yoichi TAKAHASHI, Nobumasa Awai, Hidenori Akatsuka, Takayuki Kawaguchi, Toru Iljima
-
Patent number: 8258131Abstract: The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]: wherein the ring A is a benzene ring having a substituent R1, fused to an adjacent 6-membered heterocyclic ring and further optionally having a substituent(s) other than R1, R1 is an alkylsulfonylamino group etc.Type: GrantFiled: July 21, 2008Date of Patent: September 4, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yoichi Takahashi, Nobumasa Awai, Hidenori Akatsuka, Takayuki Kawaguchi, Toru Iijima
-
Patent number: 8188073Abstract: The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of the formula: RaSO2NH— etc, Ra is an alkyl group etc, R2 and R3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(?O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 24, 2011Date of Patent: May 29, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toru Iijima, Yasuo Yamamoto, Hidenori Akatsuka, Takayuki Kawaguchi
-
Publication number: 20110251185Abstract: The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of the formula: RaSO2NH— etc, Ra is an alkyl group etc, R2 and R3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(?O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 24, 2011Publication date: October 13, 2011Inventors: Toru IIJIMA, Yasuo Yamamoto, Hidenori Akatsuka, Takayuki Kawaguchi
-
Patent number: 7998956Abstract: The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of the formula: RaSO2NH— etc, Ra is an alkyl group etc, R2 and R3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an oxygen atom etc, Y is a group of the formula: —C(?O)— etc, Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group, Q is a single bond, an alkylene group etc, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 1, 2007Date of Patent: August 16, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toru Iijima, Yasuo Yamamoto, Hidenori Akatsuka, Takayuki Kawaguchi
-
Publication number: 20100240644Abstract: The present invention provides a morpholine derivative of the formula [I]; wherein R1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R3, R4, R5 and R6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.Type: ApplicationFiled: June 16, 2008Publication date: September 23, 2010Inventors: Hidenori Akatsuka, Hiroshi Sugama, Nobumasa Awai, Takayuki Kawaguchi, Yoichi Takahashi, Toru Iijima, Jingkang Shen, Guangxin Xia, Jianshu Xie
-
Patent number: 7789059Abstract: An intake control device for an air intake system includes one or more stationary intake pipes that communicate with one or more intake ports of an engine. One or more movable intake pipes are movable relative to the stationary intake pipes and, in one position, cooperate with the stationary intake pipes to define engine air intake passages. An actuator applies a force tending to move the movable intake pipes in a first direction. A controller controls the actuator. The movable intake pipes are inhibited from moving beyond a first position in the first direction. The controller directs the actuator to apply a force to the movable intake pipes when the movable intake pipes are in the first position.Type: GrantFiled: July 20, 2007Date of Patent: September 7, 2010Assignee: Yamaha Hatsudoki Kabushiki KaishaInventors: Daichi Noborio, Hidenori Akatsuka
-
Publication number: 20100204218Abstract: The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]: wherein the ring A is a benzene ring having a substituent R1, fused to an adjacent 6-membered heterocyclic ring and further optionally having a substituent(s) other than R1, R1 is an alkylsulfonylamino group etc.Type: ApplicationFiled: July 21, 2008Publication date: August 12, 2010Inventors: Yoichi Takahashi, Nobumasa Awai, Hidenori Akatsuka, Takayuki Kawaguchi, Toru Iijima
-
Patent number: 7737161Abstract: The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and, R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.Type: GrantFiled: January 29, 2009Date of Patent: June 15, 2010Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takayuki Kawaguchi, Hidenori Akatsuka, Toru Iijima, Tatsuya Watanabe, Jun Murakami, Takashi Mitsui
-
Publication number: 20100059018Abstract: In some embodiments, a throttle control device includes an axel 43 for opening and closing a throttle valve 41, an axel sensor 52 for detecting an operation amount of the axel 43, a throttle control portion 71 for controlling the throttle valve 41, a memory portion 72 for storing a plurality of control modes 81, 82, and 83 in which a targeted throttle opening degree for the operation amount is determined, a change-over switch 122 for instructing the changing of the control mode, a judgment portion 73a for judging whether or not the operation amount of the axel 43 is equal to or less than the predetermined operation amount, and a changing portion 73b for changing the control mode when the switch 122 is operated and the operation amount of the axel 43 is equal to or less than the predetermined operation amount.Type: ApplicationFiled: September 2, 2009Publication date: March 11, 2010Applicant: YAMAHA HATSUDOKI KABUSHIKI KAISHAInventor: Hidenori Akatsuka
-
Patent number: 7605158Abstract: The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4 and R5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R3 is a hydrogen atom. etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.Type: GrantFiled: September 24, 2004Date of Patent: October 20, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takayuki Kawaguchi, Hidenori Akatsuka, Masamichi Morimoto, Tatsuya Watanabe, Toru Iijima, Jun Murakami
-
Publication number: 20090209511Abstract: The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: —N? or —CH?; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.Type: ApplicationFiled: March 24, 2009Publication date: August 20, 2009Inventors: Takayuki Kawaguchi, Hidenori Akatsuka, Toru Iijima, Yasunori Tsuboi, Takashi Mitsui, Jun Murakami
-
Publication number: 20090156803Abstract: The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and, R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.Type: ApplicationFiled: January 29, 2009Publication date: June 18, 2009Inventors: Takayuki Kawaguchi, Hidenori Akatsuka, Toru Iijima, Tatsuya Watanabe, Jun Murakami, Takashi Mitsui